Stafford-Smith Mark
Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina 27710, USA.
Curr Opin Anaesthesiol. 2007 Feb;20(1):65-9. doi: 10.1097/ACO.0b013e328013f408.
To describe the relationship of renal disease and metabolic syndrome with cardiovascular disease and explore the role of toxic solutes retained due to renal impairment as mediators of cardiovascular risk.
Metabolic syndrome and chronic kidney disease are related. Chronic kidney disease is partly caused by, but also mediates, some of the adverse effects of metabolic syndrome. Uremic toxins with potent effects have been identified. Examples include the nitric oxide synthase inhibitor asymmetric dimethyl arginine - this substance accumulates as renal function declines and has a strong relationship with cardiovascular events and mortality in a variety of populations. The effect of asymmetric dimethyl arginine in causing arterial stiffness, a phenomenon which has been linked with risk of vascular disease, offers a mechanistic explanation for the importance of this substance.
A pathophysiology that links renal impairment with cardiovascular risk has long been suspected and is being elucidated through the effects of uremic toxins.
描述肾脏疾病和代谢综合征与心血管疾病的关系,并探讨因肾功能损害而潴留的毒性溶质作为心血管风险介质的作用。
代谢综合征与慢性肾脏病相关。慢性肾脏病部分由代谢综合征的一些不良反应引起,但也介导这些不良反应。已鉴定出具有强效作用的尿毒症毒素。例如一氧化氮合酶抑制剂不对称二甲基精氨酸——随着肾功能下降,这种物质会蓄积,并且在各种人群中与心血管事件和死亡率密切相关。不对称二甲基精氨酸导致动脉僵硬的作用,这一现象与血管疾病风险相关,为该物质的重要性提供了一种机制解释。
长期以来人们一直怀疑存在一种将肾功能损害与心血管风险联系起来的病理生理学,并且正在通过尿毒症毒素的作用来阐明这一机制。